REPH stock forecast
Our latest prediction for Recro Pharma, Inc.'s stock price was made on the May 24, 2018 when the stock price was at 5.63$.
In the short term (2weeks), REPH's stock price should underperform the market by -0.27%. During that period the price should oscillate between -11.35% and +17.56%.
In the medium term (3months), REPH's stock price should outperform the market by 0.48%. During that period the price should oscillate between -22.26% and +41.91%.Get email alerts
About Recro Pharma, Inc.
Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.
At the moment the company generates 79M USD in revenues.
On its last earning announcement, the company reported a loss of -3.18$ per share.
The book value per share is 1.18$
Three months stock forecastMay 24, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|